With two years of experience selling Alzheimer’s disease antibody Leqembi so far under Eisai’s belt, the Japanese drugmaker ...

Leqembi — sold through a partnership between Eisai Co. and Cambridge-based Biogen — is one of the first medications approved ...

The European Commission has referred Eisai and Biogen’s application to an appeals committee. Elsewhere, Opthea warned of ...

There are glimmers of hope, however, with Eisai reporting last month that it is on track to meet that fiscal 2024 sales ...

A further presentation during the same symposium at AD/PD 2025 focused on how MRI methods could be accelerated to improve ...

Key regulators are not recommending Lilly’s Kisunla be cleared for the European market. The company says it plans to appeal ...

According to Eisai's simulation, Leqembi sales will reach JPY 250 to 280 billion for their financial year (FY) 2027, which ends in March 2028. Eisai's presentation can be found on https://www ...

The European Union’s CHMP said that the benefits of the drug, already approved in the U.S., do not outweigh the risk of ...

Leqembi is the result of a long-standing collaboration between BioArctic and Eisai, and the antibody was originally developed by BioArctic based on the work of Professor Lars Lannfelt and his ...

At the AD/PD 2025 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/OD), during the 'Abeta Targeting Therapies in AD' symposium on 3 April, Roche presented interim trial data for ...

STOCKHOLM, March 25, 2025 /PRNewswire/ -- BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai today published a presentation including a simulation [1] of potential future sales for Leqembi ...